

This event was made possible in large part by:

SEAN N. PARKER FOUNDATION

Additional sponsorship was provided by:

Amgen, Inc.

AvidBiotics Corp.

Bayer HealthCare

Celgene

Centers for Therapeutic Innovation, Pfizer

Daiichi Sankyo

Five Prime Therapeutics, Inc.

Flexus Biosciences, Inc.

Genentech, Inc.

Immune Design

Merck & Co., Inc.

Nektar Therapeutics


OncoSec Medical, Inc.

Sanofi



Cancer Center Symposium 2015

Breakthroughs in Cancer Immunotherapy



Thursday, March 19 9 am - 4:30 pm Cole Hall, Parnassus

cancer.ucsf.edu/2015



Morning Session

9:00 AM	Welcome
	Session 1 (Chair: Jedd D. Wolchok, MD, PhD)
9:10 AM	Mechanisms of Protective Tumor Immunity Glenn Dranoff, MD Director, Human Gene Transfer Laboratory Core, Dana-Farber Cancer Institute
9:40 AM	Immune Checkpoint Blockade: Mobilizing the Immune System to Treat Cancer Suzanne L. Topalian, MD Director, Melanoma Program, Sidney Kimmel Comprehensive Cancer Center
10:05 AM	Deciphering Human Immune Responses to Immunotherapy Lawrence Fong, MD Professor of Hematology/Oncology, UCSF Genitourinary Cancer Specialist, UCSF Medical Center
10:30 AM	Break
	Session 2 (Chair: Philip D. Greenberg, MD)
10:50 AM	Regulation of CD8 Immunity and Anti-Tumor Immunity Pamela S. Ohashi, PhD, FRSC Director, Immune Therapy Program, Ontario Cancer Institute
11:15 AM	Stromal Cell Regulation of Immunity Shannon Turley, PhD Principal Scientist, Cancer Immunology, Genentech
11:40 AM	Visualizing Immune Deviation in Tumor Microenvironments Matthew Krummel, PhD Professor of Pathology, UCSF Faculty Director, Biological Imaging Development Center, UCSF

Afternoon Session

12:05 PM	Lunch
	Session 3 (Chair: Zena Werb, PhD)
1:15 PM	Engineering Anti-Tumor Immunity with 'Hitchhiking Therapeutics' Darrell J. Irvine, PhD Professor of Biological Engineering and Materials Science & Engineering, MIT
1:40 PM	Emerging Strategies for the Immunotherapy of Pancreatic Cancer Elizabeth M. Jaffee, MD Deputy Director, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2:05 PM	Optimizing CAR T Cell Therapy: Progress and Challenges Crystal L. Mackall, MD Head of Immunology Section, Chief of the Pediatric Oncology Branch, National Cancer Institute
2:30 PM	Break
	Session 4 (Chair: Lewis Lanier, PhD)
2:50 PM	Treating the Tumor and Treating the Host Ronald Levy, MD Professor and Chief, Division of Oncology, Stanford University
3:15 PM	Using Synthetic Biology to Reprogram the T Cell Wendell Lim, PhD Professor of Cellular and Molecular Pharmacology, UCSF
3:40 PM	Updates in CAR T Cell Immunotherapy for Cancer Carl H. June, MD Program Director of Translational Research, Abramson Family Cancer Research Institute
4:20 PM	Closing Comments Alan Ashworth, PhD, FRS President, Helen Diller Family Comprehensive Cancer Center, UCSF
4:30 PM	Adjourn